아테렉토미 디바이스 : 시장 인사이트, 경쟁 구도, 시장 예측(-2032년)

Atherectomy Devices Market by Product Type (Directional, Rotational, Photoablative, and Orbital), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cardiovascular diseases, increase in prevalence of lifestyle disorders, rising awareness and screening programs, and increase in product development activities by key market players across the globe.

The atherectomy devices market was valued at USD 1,045.94 million in 2024, growing at a CAGR of 9.05% during the forecast period from 2025 to 2032, to reach USD 2,083.37 million by 2032. The rising prevalence of cardiovascular diseases and lifestyle disorders, such as diabetes and obesity, is driving the demand for atherectomy devices to treat atherosclerosis. Additionally, growing awareness and screening programs have led to earlier detection and diagnosis of arterial blockages, resulting in higher demand for atherectomy interventions. Furthermore, the advancements in atherectomy technology by key market players are improving precision and safety, making these devices more effective in treating complex cases. Together, these factors are fueling the growth of the global atherectomy device market. Collectively, these factors are expected to boost the market for atherectomy devices during the forecast period from 2025 to 2032.

Atherectomy Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2025), globally, approximately 640 million people, or about 1 in 12 individuals, live with heart and circulatory diseases.

Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affected an estimated 200 million people globally of which 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed. As CVD often leads to conditions like atherosclerosis, where plaque buildup narrows or blocks arteries, the need for effective treatments is rising. Atherectomy devices, which remove plaque and restore blood flow, are becoming essential in managing conditions such as coronary artery disease and peripheral artery disease. Thus, atherosclerosis is considered a major cause of myocardial infarctions, strokes, peripheral arterial disease, and heart attack. To avoid the progression to other serious CVDS, treatment of atherosclerosis becomes imperative wherein the application of atherectomy devices has become a norm. Therefore, the increase in the prevalence of cardiovascular diseases is projected to result in the growing demand for atherectomy devices, thereby contributing to the growth of the atherectomy devices market during the forecast period.

Moreover, another key factor that is aiding in the growth of atherectomy devices is the growing demand for minimally invasive devices and procedures. This can be attributed to the realization of advantages associated with minimally invasive approaches such as faster healing time and significantly less trauma compared to conventional techniques. Atherectomy devices such as directional atherectomy are considered to be a minimally invasive treatment and have been reported to provide a distinct advantage in the removal of obstructive intima hyperplastic or atherosclerotic lesions without the involvement of implantable devices such as stents. Furthermore, atherectomy devices help in avoiding disadvantages associated with surgical procedures such as surgical scarring and inflammation after stent implantation. Therefore, the advantages offered by atherectomy systems are expected to further drive the growth of atherectomy devices during the forecast period.

Moreover, the ongoing strategic activities among the key market players and technological advancement are further boosting the overall market of atherectomy devices across the globe. For instance, in September 2024, AngioDynamics, Inc., a leading medical technology company, announced that it had received European CE Mark approval for its Auryon Atherectomy System, an innovative device for treating Peripheral Artery Disease (PAD), including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR).

Therefore, the factors mentioned above are expected to boost the overall market of atherectomy devices across the globe during the forecast period.

However, the atherectomy procedures can lead to complications such as vessel perforation, embolization, or dissection and stringent regulatory concerns for product approvals may hinder the future market of atherectomy devices market growth.

Atherectomy Devices Market Segment Analysis:

Atherectomy Devices Market by Product Type (Directional, Rotational, Photoablative, and Orbital), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the atherectomy devices market, the orbital category is expected to hold the largest share in the year 2024. Orbital atherectomy devices are significantly boosting the overall market of atherectomy devices due to their unique advantages in treating complex cardiovascular conditions, particularly heavily calcified plaques. These devices use an orbiting mechanism to sand down calcified plaque while maintaining the integrity of the arterial walls, making them highly effective for patients with advanced atherosclerosis. Unlike traditional atherectomy devices, which may struggle with calcified lesions, orbital atherectomy systems provide more precise plaque removal, reducing the risk of arterial damage and allowing for improved blood flow. The ability to handle both peripheral artery disease (PAD) and coronary artery disease (CAD) makes orbital devices versatile and increases their demand across various cardiovascular applications.

Additionally, the technology behind orbital atherectomy allows for minimally invasive procedures, which have gained traction due to shorter recovery times, fewer complications, and less pain for patients. As healthcare providers increasingly seek out safer, more efficient treatment methods, orbital atherectomy systems are becoming a preferred option, driving their adoption in hospitals and clinics worldwide. Furthermore, continuous advancements in device design and operational safety have led to higher procedural success rates, which further enhances their reputation in the market.

Additionally, the increase in strategic activities by the key market players is also boosting the overall market of orbital atherectomy devices across the globe. For instance, in October 2023, Cardio Flow, Inc., a privately held medical device company specializing in minimally invasive devices to treat peripheral artery disease (PAD), announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FreedomFlow orbital atherectomy peripheral platform.

Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global atherectomy devices market during the forecast period.

North America is expected to dominate the overall atherectomy devices market:

Among all regions, North America is projected to hold the largest share of the global atherectomy devices market in 2024. Several key factors are driving this growth, including the rising prevalence of cardiovascular diseases such as coronary heart disease and peripheral arterial disease, along with increasing rates of obesity, hypertension, and diabetes. Additionally, the growing elderly population and rising government initiatives focused on disease awareness and treatment are contributing to the market expansion across the region.

As per the recent data from the Centers for Disease Control and Prevention (CDC, 2024), approximately 4.9% of U.S. adults were diagnosed with coronary heart disease in 2022. Moreover, by 2023, an estimated 12.1 million Americans were projected to have atrial fibrillation (AF). Each year, over 795,000 people in the U.S. suffer a stroke, with around 610,000 of these being first-time occurrences. Notably, nearly 185,000 strokes about one in four occur in individuals who have previously had a stroke.

The increasing incidence of AF and strokes significantly contributes to the demand for atherectomy devices. AF elevates the risk of blood clot formation, which can lead to atherosclerosis and subsequent stroke conditions requiring the removal of arterial plaque to restore proper blood flow. Atherectomy devices play a critical role in treating these vascular complications by removing blockages, particularly in AF patients who are more prone to such conditions.

Diabetes is another major contributor to the rising demand for atherectomy devices. Elevated blood glucose levels in diabetic patients can accelerate plaque buildup in the arteries, resulting in narrowing or blockages. According to the CDC (2024), an estimated 38.4 million people in the U.S. 11.6% of the total population had diabetes, with 38 million of them aged 18 and older (14.7% of U.S. adults). If left untreated, diabetes can reduce blood flow to the lower extremities and increase the risk of ulcers, infections, and even amputations. Atherectomy devices are vital in restoring proper circulation by clearing arterial blockages in diabetic patients, thereby supporting market growth.

In addition, extensive product development activities in North America, especially in the United States, are further driving market demand. For instance, in October 2023, Cardio Flow, Inc. announced it had received FDA 510(k) clearance for its FreedomFlow(TM) Orbital Atherectomy Peripheral Platform, designed to treat peripheral artery disease (PAD).

In summary, the combination of high disease burden, a large at-risk population, supportive government initiatives, and technological advancements is expected to significantly boost the North American atherectomy devices market during the forecast period.

Atherectomy Devices Market Key Players:

Some of the key market players operating in the atherectomy devices market include Koninklijke Philips N.V., Medtronic PLC, Boston Scientific Corporation, AngioDynamics Inc., Cardiovascular Systems Inc., Avinger, BD, Ra Medical Systems, REX Medical, Cardio Flow, Inc., and others.

Recent Developmental Activities in the Atherectomy Devices Market:

• In February 2023, Abbott and Cardiovascular Systems, Inc. (CSI), announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
• In October, 2022, Cardiovascular Systems, Inc., a medical device company focused on developing innovative interventional treatment systems for peripheral and coronary artery disease, announced the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems.

Key takeaways from the atherectomy devices market report study:

• Market size analysis for current atherectomy devices size (2023), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the atherectomy devices market.
• Various opportunities available for the other competitors in the atherectomy devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current atherectomy devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for atherectomy devices market growth in the coming future?

Target audience who can benefit from this atherectomy devices market report study:

• Atherectomy device product providers
• Research organizations and consulting companies
• Atherectomy devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in atherectomy devices
• Various end-users who want to know more about the atherectomy devices market and the latest technological developments in the atherectomy devices market.

Frequently Asked Questions for the Atherectomy Devices Market:

1. What are atherectomy devices?

• Atherectomy devices are medical devices that help in plaque removal from peripheral as well as coronary vasculature by cutting, shaving, sanding, or vaporizing the plaque deposits.

2. What is the market for atherectomy devices?

• The atherectomy devices market was valued at USD 1,045.94 million in 2024, growing at a CAGR of 9.05% during the forecast period from 2025 to 2032, to reach USD 2,083.37 million by 2032.

3. What are the drivers for the atherectomy devices market?

• The rising prevalence of cardiovascular diseases and lifestyle disorders, such as diabetes and obesity, is driving the demand for atherectomy devices to treat atherosclerosis. Additionally, growing awareness and screening programs have led to earlier detection and diagnosis of arterial blockages, resulting in higher demand for atherectomy interventions. Furthermore, the advancements in atherectomy technology by key market players are improving precision and safety, making these devices more effective in treating complex cases. Together, these factors are fueling the growth of the global atherectomy device market. Collectively, these factors are expected to boost the market for atherectomy devices during the forecast period from 2025 to 2032.

4. Who are the key players operating in the atherectomy devices market?

• Some of the key market players operating in the atherectomy devices market include Koninklijke Philips N.V., Medtronic PLC, Boston Scientific Corporation, AngioDynamics Inc., Cardiovascular Systems Inc., Avinger, BD, Ra Medical Systems, REX Medical, Cardio Flow, Inc., and others.

5. Which region has the highest share in the atherectomy devices market?

• Among all the regions, North America is expected to hold the largest share of the global atherectomy devices market in 2024. The key driving factors of the atherectomy devices market are the rising prevalence of cardiovascular diseases like coronary heart disease, and peripheral arterial disease, the increasing prevalence of obesity, hypertension, and diabetes, and the rising aging population, along with the rising government initiatives regarding disease treatment awareness. These factors are expected to boost the market of atherectomy devices across the region during the forecasted period.

Table of Contents

1. Atherectomy Devices Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Atherectomy Devices Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Atherectomy Devices Market Key Factors Analysis

• 5.1. Atherectomy Devices Market Drivers
  • 5.1.1. The rising prevalence of cardiovascular diseases
  • 5.1.2. Increase in prevalence of lifestyle disorders
  • 5.1.3. Increase in product development activities by key market players across the globe.
• 5.2. Atherectomy Devices Market Restraints and Challenges
  • 5.2.1. Risk of complications such as vessel perforation
  • 5.2.2. Stringent regulatory concerns
• 5.3. Atherectomy Devices Market Opportunities
  • 5.3.1. Ongoing innovations in atherectomy technology, such as the development of more effective, safer, and user-friendly devices

6. Atherectomy Devices Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Atherectomy Devices Market Assessment

• 7.1. By Product Type
  • 7.1.1. Directional
  • 7.1.2. Rotational
  • 7.1.3. Photoablative
  • 7.1.4. Orbital
• 7.2. By End-User
  • 7.2.1. Hospitals
  • 7.2.2. Specialty Clinics
  • 7.2.3. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.1.2. Canada Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.1.3. Mexico Atherectomy Devices Market Size in USD million (2022-2032)
  • 7.3.2. Europe
    • 7.3.2.1. France Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.2.2. Germany Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.2.3. United Kingdom Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.2.4. Italy Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.2.5. Spain Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.2.6. Rest of Europe Atherectomy Devices Market Size in USD million (2022-2032)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.3.2. Japan Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.3.3. India Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.3.4. Australia Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.3.5. South Korea Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.3.6. Rest of Asia-Pacific Atherectomy Devices Market Size in USD million (2022-2032)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.4.2. Africa Atherectomy Devices Market Size in USD million (2022-2032)
    • 7.3.4.3. South America Atherectomy Devices Market Size in USD million (2022-2032)

8. Atherectomy Devices Market Company and Product Profiles

• 8.1. Koninklijke Philips N.V.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Medtronic
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Boston Scientific Corporation
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. AngioDynamics Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Cardiovascular Systems Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Avinger
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. BD
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Ra Medical Systems
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. REX Medical
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Cardio Flow, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us